Patents by Inventor Meghan Drummond-Samuelson
Meghan Drummond-Samuelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11891618Abstract: Non-human animal cells and non-human animals comprising a humanized TTR locus comprising a beta-slip mutation and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus comprising a beta-slip mutation express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.Type: GrantFiled: June 3, 2020Date of Patent: February 6, 2024Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Jeffery Haines, Keith Crosby, Meghan Drummond Samuelson, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
-
Publication number: 20240002839Abstract: Disclosed are cell lines that stably express CRISPR SAM complex which comprise a gRNA that specifically targets a promoter of a gene, wherein the gene is not normally expressed in said cell. Also disclosed are methods of measuring the ability of a vector to transfer a nucleic acid molecule into such cell lines.Type: ApplicationFiled: December 2, 2021Publication date: January 4, 2024Applicant: Decibel Therapeutics, Inc.Inventors: Meghan DRUMMOND SAMUELSON, Leah SABIN, Sarah CANCELARICH
-
Publication number: 20230366024Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: April 19, 2023Publication date: November 16, 2023Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Patent number: 11674177Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.Type: GrantFiled: May 4, 2021Date of Patent: June 13, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Publication number: 20230123787Abstract: This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.Type: ApplicationFiled: August 10, 2022Publication date: April 20, 2023Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Meghan Drummond Samuelson, Brian Zambrowicz, Ka-Man Venus Lai, Charleen Hunt, Susannah Brydges, Andrew J. Murphy, Claudia Gonzaga-Jauregui, Jose Rojas, Nicole Alessandri-Haber, Robert Breese, Susan D. Croll
-
Publication number: 20230102342Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus comprising a V30M mutation and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human TTR protein or a chimeric TTR protein, fragments of which are from human TTR. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.Type: ApplicationFiled: March 23, 2021Publication date: March 30, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Meghan Drummond Samuelson, Jeffery Haines, Charleen Hunt, Guochun Gong, Brian Zambrowicz
-
Publication number: 20230078551Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.Type: ApplicationFiled: November 22, 2022Publication date: March 16, 2023Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Meghan Drummond Samuelson, Jeffery Haines, Suzanne Hartford, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
-
Patent number: 11470828Abstract: This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.Type: GrantFiled: January 16, 2020Date of Patent: October 18, 2022Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Meghan Drummond Samuelson, Brian Zambrowicz, Ka-Man Venus Lai, Charleen Hunt, Susannah Brydges, Andrew J. Murphy, Claudia Gonzaga-Jauregui, Jose Rojas, Nicole Alessandri-Haber, Robert Breese, Susan D. Croll
-
COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
Publication number: 20220265865Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with a mutation in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF isoform 5 protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF isoform 5 protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.Type: ApplicationFiled: April 29, 2022Publication date: August 25, 2022Inventors: Joseph BURNS, Kathryn ELLIS, Tyler GIBSON, Adam PALERMO, Martin SCHWANDER, Jonathon WHITTON, Leah SABIN, Christos KYRATSOUS, Meghan DRUMMOND SAMUELSON -
Publication number: 20220064735Abstract: The present disclosure provides methods of treating patients having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, methods of detecting human Synaptojanin-2 (SYNJ2) variant nucleic acid molecules and variant polypeptides, and SYNJ2 variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: November 12, 2021Publication date: March 3, 2022Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS
Publication number: 20210395781Abstract: The disclosure features compositions and methods for the treatment of sensorineural hearing loss and auditory neuropathy, particularly forms of the disease that are associated with mutations in otoferlin (OTOF), by way of OTOF gene therapy. The disclosure provides a variety of compositions that include a first nucleic acid vector that contains a polynucleotide encoding an N-terminal portion of an OTOF protein and a second nucleic acid vector that contains a polynucleotide encoding a C-terminal portion of an OTOF protein. These vectors can be used to increase the expression of OTOF in a subject, such as a human subject suffering from sensorineural hearing loss.Type: ApplicationFiled: August 6, 2021Publication date: December 23, 2021Inventors: Joseph BURNS, Kathryn ELLIS, Adam PALERMO, Martin SCHWANDER, Jonathon WHITTON, Leah SABIN, Christos KYRATSOUS, Meghan DRUMMOND SAMUELSON -
Publication number: 20210388045Abstract: The disclosure provides polynucleotides containing regions of the Myosin 15 (Myo15) promoter, as well as vectors containing the same, that can be used to promote expression of a transgene specifically in hair cells. The polynucleotides described herein may be operably linked to a transgene, such as a transgene encoding a therapeutic protein, so as to promote hair cell-specific expression of the transgene. The polynucleotides described herein may be operably linked to a therapeutic transgene and used for the treatment of subjects having or at risk of developing hearing loss or vestibular dysfunction.Type: ApplicationFiled: August 6, 2021Publication date: December 16, 2021Inventors: Joseph BURNS, Kathryn ELLIS, Adam PALERMO, Martin SCHWANDER, Jonathon WHITTON, Leah SABIN, Christos KYRATSOUS, Meghan DRUMMOND SAMUELSON
-
Publication number: 20210371930Abstract: The present disclosure provides methods of treating a subject having hearing loss, methods of identifying a subject having an increased risk of developing hearing loss, and methods of detecting Solute Carrier Family 26 Member 5 (SLC26A5) variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: May 5, 2021Publication date: December 2, 2021Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Publication number: 20210348228Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting Kelch Domain Containing 7B (KLHDC7B) variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: May 4, 2021Publication date: November 11, 2021Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Publication number: 20210300976Abstract: The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting human Fascin-2 (FSCN2) variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: March 5, 2021Publication date: September 30, 2021Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Publication number: 20200385760Abstract: Non-human animal cells and non-human animals comprising a humanized TTR locus comprising a beta-slip mutation and methods of using such non-human animal cells and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus comprising a beta-slip mutation express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR.Type: ApplicationFiled: June 3, 2020Publication date: December 10, 2020Inventors: Jeffery Haines, Keith Crosby, Meghan Drummond-Samuelson, David Frendewey, Brian Zambrowicz, Andrew J. Murphy
-
Publication number: 20200370119Abstract: The present disclosure provides methods of treating patients having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, methods of detecting human Synaptojanin-2 (SYNJ2) variant nucleic acid molecules and variant polypeptides, and SYNJ2 variant nucleic acid molecules and variant polypeptides.Type: ApplicationFiled: May 22, 2020Publication date: November 26, 2020Inventors: Kavita Praveen, Giovanni Coppola, Manuel Allen Revez Ferreira, Lauren Gurski, Aris Baras, Meghan Drummond Samuelson, Goncalo Abecasis
-
Publication number: 20200229409Abstract: This disclosure relates to an animal model of human disease. More specifically, this disclosure relates to a rodent model of mood disorders such as unipolar depression and an anxiety disorder. Disclosed herein are genetically modified rodent animals that carry a humanized G protein-coupled receptor 156 (GPR156) gene that encodes a mutant human GPR156 protein comprising Asp at an amino acid position corresponding to position 533 in a full length wild type human GPR156 protein.Type: ApplicationFiled: January 16, 2020Publication date: July 23, 2020Inventors: Meghan Drummond Samuelson, Brian Zambrowicz, Ka-Man Venus Lai, Charleen Hunt, Susannah Brydges, Andrew J. Murphy, Claudia Gonzaga-Jauregui, Jose Rojas, Nicole Alessandri-Haber, Robert Breese, Susan D. Croll
-
Publication number: 20190098879Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized TTR locus and methods of using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized TTR locus express a human transthyretin protein or a chimeric transthyretin protein, fragments of which are from human transthyretin. Methods are provided for using such non-human animals comprising a humanized TTR locus to assess in vivo efficacy of human-TTR-targeting reagents such as nuclease agents designed to target human TTR. Methods are also provided for making such non-human animals comprising a humanized TTR locus.Type: ApplicationFiled: September 28, 2018Publication date: April 4, 2019Inventors: Meghan Drummond-Samuelson, Jeffery Haines, Suzanne Hartford, David Frendewey, Brian Zambrowicz, Andrew J. Murphy